A Phase 1 interventional study of Ventrix Bio Extracellular Matrix in Hypoplastic Left Heart Syndrome, sponsored by Emory University. Not yet recruiting at 1 site in United States. Open to participants aged Up to 1 Year. Per ClinicalTrials.gov, last updated 2025-03-10.
Sponsored by Emory University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 22nd largest by planned enrollment of the 26 interventional ones that give a count, is one of 2 that started in 2025, is one of 9 in phase 1, and was the 42nd registered.
67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.
Browse Hypoplastic Left Heart Syndrome studies →6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:
HeartWorks, Inc. · Sites in United States
Ages 0+
Queen Silvia Children's Hospital, Gothenburg, Sweden · Sites in United States, Austria, Canada and 5 more countries
Ages 23 wk–31 wk
Nationwide Children's Hospital · Sites in United States
Children's Hospital Medical Center, Cincinnati · Sites in United States, Canada, United Kingdom
Ages up to 15 mo
Mauro H. Schenone · Sites in United States
Ages up to 45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: Up to 1 Year · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 7 · Phase 3 2
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 12 is below the median of 30 across 41 interventional studies indexed under Hypoplastic Left Heart Syndrome.
Median enrollment 30 across the 26 interventional studies, 96 across the 18 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 44 have an industry lead sponsor. The 10 most frequent:
Emory University is the lead sponsor of 1,406 studies on the registry; 224 are open to participants now.
Of its 238 completed or terminated interventional studies of FDA-regulated products, 179 (75%) have results posted.
Emory University has 5 studies filed under Hypoplastic Left Heart Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this Phase I Open-Label study is to demonstrate the safety and feasibility of VentriGel injection in children with Hypoplastic Left Heart Syndrome (HLHS).
The main questions it aims to answer are:
HLHS, a type of congenital heart disease, presents a unique challenge where the left ventricle fails to develop, necessitating the right ventricle to manage both systemic and pulmonary blood flow. This condition, once fatal, has become manageable due to advancements in surgical techniques, with reported 5-year survival rates of 70-90%. However, these staged procedures, while lifesaving, can strain the right ventricle, leading to long-term issues such as weakened muscle and reduced cardiac function. Additionally, even with surgical intervention, patients often face a diminished quality of life.
Addressing these challenges, ongoing clinical trials explore regenerative therapies, particularly stem cell injections, aiming to improve heart function. Yet, concerns persist regarding the practicality and efficacy of these treatments, including issues with cell survival and coordination of injections within narrow timeframes.
Innovatively, the investigator and the team propose an alternative approach using VentriGel, an injectable hydrogel derived from decellularized porcine myocardium. Originally designed for treating heart failure post-myocardial infarction in adults, VentriGel has shown promising results in animal models, demonstrating significant improvements in cardiac function. Notably, its shelf-stable nature and flexible timing for administration offer advantages over traditional stem cell therapies.
Moreover, VentriGel's effectiveness in addressing right-ventricular failure, as demonstrated in recent studies, highlights its potential as a solution for HLHS patients. Leveraging approved extracellular matrix devices, such as Alloderm and SurgiSIS, further underscores the feasibility and safety of this approach, paving the way for potentially transformative treatments in congenital heart diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment intervention of a total of 8 injections into the right ventricle of the heart will occur before the patient comes off of the heart-lung bypass machine used during the Stage II Glenn Operation. The treatment will be conducted according to clinical guidelines set in place while the patient is undergoing a surgical intervention before the patient comes off the heart/lung bypass machine required for the stage II Glenn Procedure.
Drug: Ventrix Bio Extracellular Matrix
VentriGel will be administered by injection into the right ventricle of the heart in the following defined doses per injection. There will be a total of 8 injections. The proposed dose of up to 0.6 mL is administered as up to 8 sequential injections of 4 injections of 0.1 mL each and 4 injections of 0.05 mL each.
Also known as: VentriGel
Number of ventricular tachycardia events
Number of sustained/symptomatic ventricular tachycardia incidences requiring intervention with inotropic support or anti-arrhythmics
Time frame: upto 30 days post operation
Number of Cardiogenic shock events
Cardiogenic shock (i.e. tissue hypoperfusion presented by hypotension due to decreased cardiac output, determined by rising lactate levels (5x normal levels in first 24 hours, 2.5x normal levels in first 30 days)
Time frame: Day 1, 30 days post operation
Number of unplanned cardiovascular operation events
Unplanned cardiovascular operation due to right ventricular intramyocardial injection site bleeding in the first 5 days after Stage II operation decreased cardiac output, determined by rising lactate levels (5x normal levels in first 24 hours, 2.5x normal levels in first 30 days)
Time frame: 30 days post operation
Number of patients requiring new permanent pacemaker
Number of patients requiring new permanent pacemaker
Time frame: upto 30 days post operation
Stroke or embolic event
Stroke or embolic event to the brain determined by CT scan
Time frame: upto 30 days post operation
Number of Adverse Events
Number of adverse events occurring post op
Time frame: upto 30 days post operation
Number of deaths
Number of deaths occurring post op
Time frame: upto 30 days post operation
Number of VentriGel products manufactured and delivered to subjects
Time frame: 12 months
Number of patients receiving Cardiac MRIs
Time frame: Baseline, 6 months, 12 months
Change in right ventricular ejection fraction
This will be measured by serial echocardiograms and MRI scans
Time frame: Baseline, 6 months, 12 months post operation
Change in right ventricular end diastolic volume
This will be measured by serial echocardiograms and MRI scans
Time frame: Baseline, 6 months, 12 months post operation
Change in right ventricular end systolic volume
This will be measured by serial echocardiograms and MRI scans
Time frame: Baseline, 6 months, 12 months post operation
Change in tricuspid regurgitation
This will be measured by serial echocardiograms and MRI scans. tricuspid regurgitation measured by tricuspid valve vena contracta width
Time frame: Baseline, 6 months,12 months post operation
Change in right ventricular function Fractional Area Change
This will be measured by serial transthoracic echocardiogram (TTE)
Time frame: Baseline, 6 months,12 months post operation
Change in right ventricular global longitudinal strain
This will be measured by serial transthoracic echocardiogram (TTE)
Time frame: Baseline, 6 months,12 months post operation
Change in right ventricular global circumferential strain
This will be measured by serial transthoracic echocardiogram (TTE)
Time frame: Baseline, 6 months,12 months post operation
Change in right ventricular Tricuspid Annular Plane Systolic Excursion (TAPSE)
This will be measured by serial transthoracic echocardiogram (TTE)
Time frame: Baseline, 6 months,12 months post operation
Change in right atrial volume indexed
This will be measured by serial transthoracic echocardiogram (TTE)
Time frame: Baseline, 6 months,12 months post operation
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2025; primary completion for Sep 2028, 37 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hypoplastic Left Heart Syndrome →